Ranbaxy unit to commercialize Daiichi Sankyo drugs in Mexico

Japanese drug major Daiichi Sankyo's portfolio of drugs is to be commercialized in Mexico through a recently created marketing division within Ranbaxy Mexico SA, a subsidiary of Indian firm Ranbaxy. This is the first time in Latin America that Daiichi Sankyo and Ranbaxy are leveraging mutual synergies generated through the Hybrid Business Model, they note.

Remarking on the development, Takashi Shoda, chief executive of Daiichi Sankyo, said: "We are dedicated to realize various synergies through our hybrid business model which enables both companies to fully realize their strengths...I believe our products will offer an excellent therapy option to the doctors and patients in Mexico."

Commenting on the occasion, Atul Sobti, CEO and managing director of Ranbaxy, said, 'The creation of a Daiichi Sankyo Division within Ranbaxy Mexico marks our first endeavor in creating a dedicated marketing arm for Daiichi Sankyo's portfolio of innovator products. Our understanding of Latin American markets and local presence pave the way for an efficient and immediate market entry for Daiichi Sankyo, while priming the channel for the launch of Ranbaxy speciality products in the future.'

This hybrid model will enable the two companies to leverage their respective strengths in the dominant prescription segment, through the newly created Division, while continuing expansion in the rapidly evolving generics market.